JACC: Basic to Translational Science (Aug 2016)

A Cell-Enriched Engineered Myocardial Graft Limits Infarct Size and Improves Cardiac Function

  • Isaac Perea-Gil, MS,
  • Cristina Prat-Vidal, PhD,
  • Carolina Gálvez-Montón, DVM, PhD,
  • Santiago Roura, PhD,
  • Aida Llucià-Valldeperas, PhD,
  • Carolina Soler-Botija, PhD,
  • Oriol Iborra-Egea, MS,
  • Idoia Díaz-Güemes, DVM, PhD,
  • Verónica Crisóstomo, DVM, PhD,
  • Francisco M. Sánchez-Margallo, DVM, PhD,
  • Antoni Bayes-Genis, MD, PhD

DOI
https://doi.org/10.1016/j.jacbts.2016.06.005
Journal volume & issue
Vol. 1, no. 5
pp. 360 – 372

Abstract

Read online

Myocardial infarction (MI) remains a dreadful disease around the world, causing irreversible sequelae that shorten life expectancy and reduce quality of life despite current treatment. Here, the authors engineered a cell-enriched myocardial graft, composed of a decellularized myocardial matrix refilled with adipose tissue-derived progenitor cells (EMG-ATDPC). Once applied over the infarcted area in the swine MI model, the EMG-ATDPC improved cardiac function, reduced infarct size, attenuated fibrosis progression, and promoted neovascularization of the ischemic myocardium. The beneficial effects exerted by the EMG-ATDPC and the absence of identified adverse side effects should facilitate its clinical translation as a novel MI therapy in humans.

Keywords